Baudax Bio Signs Non-Binding Term Sheet for Debt Facility
March 04, 2020 11:42 ET
|
Baudax Bio, Inc.
MALVERN, Pa., March 04, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that, as part of its...
Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain
February 20, 2020 16:05 ET
|
Baudax Bio, Inc.
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S. Commercial Launch Planned to Commence in Late April or Early May 2020 Management to Host...
Baudax Bio Reports 2019 Annual Financial Results
February 13, 2020 16:08 ET
|
Baudax Bio, Inc.
FDA Grants Appeal for IV Meloxicam New Drug Application PDUFA Goal Date of February 20, 2020 MALVERN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical...
Baudax Bio Announces PDUFA Date for Intravenous Meloxicam
January 22, 2020 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a specialty pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food...
Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference
December 03, 2019 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other...